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Abstract
Screening and surveillance are routinely used in medicine for early detection of disease and
close monitoring of progression. Biomarkers are one of the primarily tools used for these
tasks, but their successful translation to clinical practice is closely linked to their ability
to accurately predict clinical endpoints during follow-up. Motivated by a study of patients
who received a human tissue valve in the aortic position, in this work we are interested in
optimizing and personalizing screening intervals for longitudinal biomarker measurements.
Our aim in this paper is twofold: First, to appropriately select the model to use at time
t, the time point the patient was still event-free, and second, based on this model to select
the optimal time point u > t to plan the next measurement. To achieve these two goals
we develop measures based on information theory quantities that assess the information we
gain for the conditional survival process given the history of the subject that includes both
baseline information and his/her accumulated longitudinal measurements.
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1 Introduction
Decision making in medicine has become increasingly complex for patients and practitioners.
This has resulted from factors such as the shift away from physician authority toward shared
decision making, unfiltered information on the Internet, new technology providing additional
data, numerous treatment options with associated risks and benefits, and results from new
clinical studies. Within this context medical screening procedures are routinely performed
for several diseases. Most prominent examples can be found in cancer research, where,
for example, mammographic screening is performed for the detection of breast cancer in
asymptomatic patients, and prostate-specific antigen (PSA) levels are used to monitor the
progression of prostate cancer in men who had already been diagnosed with the disease. In
general, the aim of screening procedures is to optimize the benefits, i.e., early detection of
disease or deterioration of the condition of a patient, while also balancing the respective
costs. In this paper we are interested in optimizing screening intervals for asymptomatic or
symptomatic patients that are followed-up prospectively (the latter possibly after a medical
procedure). The setting we focus on is better explained via Figure 1. More specifically, this
figure depicts a hypothetical patient who has been followed-up up to time point t, and has
provided a set of longitudinal biomarker measurements. Using this information, physicians
are interested in events occurring within a medically relevant time interval (t, t + ∆t]. If
the probability of surviving beyond t + ∆t is lower than the pre-specified constant c(t),
then the physician is supposed to immediately take action to improve the prospects for this
patient. However, when the chance of surviving until t + ∆t is higher than c(t), then the
physician may not initiate treatment or require an invasive test, and instead wishes to gain
a better understanding of the disease progression using additional biomarker measurements.
The decision to request an additional measurement requires careful weighing of the potential
benefits and costs to the patient and health care system. Hence, we are interested in carefully
planning the timing of the next measurement in order to maximize the information we can
gain on disease progression, and at the same time minimize costs and patient burden.
Statistical methods for optimizing medical screening strategies have flourished in the past
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Figure 1: Illustration of a patient’s longitudinal profile up to time t, and conditional survival
function for whom we wish to plan an extra measurement. Physicians are interested in
events occurring within the time interval (t, t + ∆t]. Constant c(t) defines the threshold
above which the physician requires extra information before making a decision.
years. These methods have been primarily based on Markov and multistate models (Son-
nenberg and Beck 1993; Parmigiani 1993; Lee and Zelen 1998; Parmigiani 1998, 1999, 2002;
Schaefer et al. 2004; Alagoz et al. 2010). The appealing feature of these models is that they
can simultaneously handle different medical options and select the one that provides the
most gains at an acceptable cost (cost-effectiveness). Here we will instead work under the
framework of joint models for longitudinal and time-to-event data (Henderson et al. 2000;
Tsiatis and Davidian 2004; Rizopoulos 2012). An advantageous feature of joint models is
that they utilize random effects and therefore have an inherent subject-specific nature. This
allows one to better tailor decisions to individual patients, i.e., personalize screening, rather
than using the same screening rule for all. In addition, contrary to the majority of screen-
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ing approaches that are based on a dichotomized version of the last available biomarker
measurement to indicate the need for a further medical procedure (e.g., PSA greater than
4.0 ng/mL), joint models utilize the whole longitudinal history to reach a decision without
requiring dichotomization of the longitudinal outcome. Our methodological developments
couple joint models with information theory quantities, following similar arguments as in
Commenges et al. (2012). In particular, our aim in this paper is twofold: First, to appropri-
ately select the joint model to use at time t, i.e. the time point the subject of interest is still
event-free, and second, based on this model to select the optimal time point u > t to plan
the next measurement. We measure optimality by the amount of information gained for
the survival process given the history of the subject of interest that includes both baseline
information and his/her accumulated longitudinal measurements. Depending on the charac-
teristics of the disease under study, the physician may request that u lies within the interval
(t, t + ∆t] or set another upper time limit after which he/she is not willing to wait before
obtaining the next measurement.
The motivation for this research comes from an aortic valve study conducted by the
Department of Cardio-Thoracic Surgery of the Erasmus Medical Center in the Netherlands.
This study includes 285 patients who received a human tissue valve in the aortic position in
the hospital from 1987 until 2008 (Bekkers et al. 2011). Aortic allograft implantation has
been widely used for a variety of aortic valve or aortic root diseases. Major advantages as-
cribed to allografts are the excellent hemodynamic characteristics as a valve substitute; the
low rate of thrombo-embolic complications, and, therefore, absence of the need for anticoag-
ulant treatment and the resistance to endocarditis. A major disadvantage of using human
tissue valves, however is the susceptibility to degeneration and the concomitant need for
re-interventions. The durability of a cryopreserved aortic allograft is age-dependent, leading
to a high lifetime risk of re-operation, especially for young patients. Re-operations on the
aortic root are complex, with substantial re-operative risks, and mortality rates in the range
of 4–12%. A timely well-planned re-operation has lower mortality risks compared to urgent
and re-operative surgery. It is therefore of great interest for cardiologists and cardio-thoracic
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surgeons to plan in the best possible manner echocardiographic assessments that will inform
them about the future prospect of a patient with a human tissue valve in order to optimize
medical care, carefully plan re-operation and minimize valve-related morbidity and mortality.
The rest of the paper is organized as follows. Section 2 briefly presents the joint modeling
framework that sets the basis for our later methodological developments. Section 3 presents
the information theory quantities that can be used to select the joint model at a particular
follow-up time, and Section 4 the corresponding quantities for planning the next longitudinal
measurement. Section 5 illustrates the use of these information measures in the Aortic Valve
study, and Section 6 concludes the paper.
2 Joint Model Specification
In this section we present a general definition of the framework of joint models for longitu-
dinal and survival data that will be used later on for planning the optimal visit schedule.
Let Dn = {Ti, δi,yi; i = 1, . . . , n} denote a sample from the target population, where T ∗i
denotes the true event time for the i-th subject, Ci the censoring time, Ti = min(T
∗
i , Ci) the
corresponding observed event time, and δi = I(T
∗
i ≤ Ci) the event indicator, with I(·) being
the indicator function that takes the value 1 when T ∗i ≤ Ci, and 0 otherwise. In addition,
we let yi denote the ni × 1 longitudinal response vector for the i-th subject, with element
yil denoting the value of the longitudinal outcome taken at time point til, l = 1, . . . , ni.
To accommodate different types of longitudinal responses in a unified framework, we
postulate a generalized linear mixed effects model. In particular, the conditional distribution
of yi given a vector of random effects bi is assumed to be a member of the exponential family,
with linear predictor given by
k
[
E{yi(t) | bi}
]
= ηi(t) = x
>
i (t)β + z
>
i (t)bi, (1)
where k(·) denotes a known one-to-one monotonic link function, and yi(t) denotes the value of
the longitudinal outcome for the i-th subject at time point t, xi(t) and zi(t) denote the time-
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dependent design vectors for the fixed-effects β and for the random effects bi, respectively.
The random effects are assumed to follow a multivariate normal distribution with mean zero
and variance-covariance matrix D. For the survival process, we assume that the risk for an
event depends on a function of the subject-specific linear predictor ηi(t) and/or the random
effects. More specifically, we have
hi(t | Hi(t),wi) = lim
∆t→0
Pr{t ≤ T ∗i < t+ ∆t | T ∗i ≥ t,Hi(t),wi}
/
∆t
= h0(t) exp
[
γ>wi + f{ηi(t), bi,α}
]
, t > 0, (2)
where Hi(t) = {ηi(s), 0 ≤ s < t} denotes the history of the underlying longitudinal process
up to t, h0(·) denotes the baseline hazard function, wi is a vector of baseline covariates with
corresponding regression coefficients γ. Function f(·), parameterized by vector α, specifies
which components/features of the longitudinal outcome process are included in the linear
predictor of the relative risk model. Some examples, motivated by the literature (Brown
2009; Rizopoulos and Ghosh 2011; Rizopoulos 2012; Taylor et al. 2013; Rizopoulos et al.
2014), are:
f{Hi(t), bi,α} = αηi(t),
f{Hi(t), bi,α} = α1ηi(t) + α2η′i(t), with η′i(t) =
dηi(t)
dt
,
f{Hi(t), bi,α} = α
∫ t
0
ηi(s) ds,
f{Hi(t), bi,α} = α>bi.
These formulations of f(·) postulate that the hazard of an event at time t may be associated
with the underlying level of the biomarker at the same time point, the slope of the longitu-
dinal profile at t, the accumulated longitudinal process up to t, or the random effects alone.
Finally, the baseline hazard function h0(·) is modeled flexibly using a B-splines approach,
i.e.,
log h0(t) = γh0,0 +
Q∑
q=1
γh0,qBq(t,v), (3)
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where Bq(t,v) denotes the q-th basis function of a B-spline with knots v1, . . . , vQ and γh0
the vector of spline coefficients. To avoid the task of choosing the appropriate number
and position of the knots, we include a relatively high number of knots (e.g., 15 to 20)
and appropriately penalize the B-spline regression coefficients γh0 for smoothness using the
differences penalty (Eilers and Marx 1996).
For the estimation of joint model’s parameters we use a Bayesian approach based on
Markov chain Monte Carlo (MCMC) algorithms. The expression for the posterior distribu-
tion of the model parameters given the observed data is derived under the assumptions that
given the random effects, both the longitudinal and event time process are assumed inde-
pendent, and the longitudinal responses of each subject are assumed independent. Formally
we have,
p(yi, Ti, δi | bi,θ) = p(yi | bi,θ) p(Ti, δi | bi,θ), (4)
p(yi | bi,θ) =
∏
l
p(yil | bi,θ), (5)
where θ denotes the full parameter vector, and p(·) denotes an appropriate probability
density function. Under these assumptions the posterior distribution is analogous to:
p(θ, b) ∝
n∏
i=1
ni∏
l=1
p(yil | bi,θ) p(Ti, δi | bi,θ) p(bi | θ) p(θ), (6)
where
p(yil | bi,θ) = exp
{[
yilψil(bi)− c{ψil(bi)}
]/
a(ϕ)− d(yil, ϕ)
}
,
with ψil(bi) and ϕ denoting the natural and dispersion parameters in the exponential family,
respectively, c(·), a(·), and d(·) are known functions specifying the member of the exponential
family, and for the survival part
p(Ti, δi | bi,θ) = hi(Ti | Hi(Ti, bi))δi exp
{
−
∫ Ti
0
hi(s | Hi(s, bi)) ds
}
,
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with hi(·) given by (2). The integral in the definition of the survival function
Si(t | Hi(t), bi,wi) = exp
{
−
∫ t
0
h0(s) exp
[
γ>wi + f{ηi(s), bi,α}
]
ds
}
, (7)
does not have a closed-form solution, and thus a numerical method must be employed for its
evaluation. Standard options are the Gauss-Kronrod and Gauss-Legendre quadrature rule.
The penalized version of the B-spline approximation to the baseline hazard can be fitted
by specifying for γh0 the improper prior (Lang and Brezger 2004):
p(γh0 | τh) ∝ τ ρ(K)/2h exp
(
−τh
2
γ>h0Kγh0
)
,
where τh is the smoothing parameter that takes a Gamma(1, τhδ) prior distribution, with
a hyper-prior τhδ ∼ Gamma(10−3, 10−3), which ensures a proper posterior distribution for
γh0 (Jullion and Lambert 2007), K = ∆
>
r ∆r + 10
−6I, with ∆r denoting the r-th difference
penalty matrix, and ρ(K) denotes the rank of K.
3 Choosing the Model to Use at Time t
As motivated in Section 1, our aim is to decide the appropriate time point to plan the next
measurement for a new subject j from the same population (i.e., with j 6∈ {i = 1, . . . , n}),
whose survival chance at a particular time point t lies within the interval [c(t), 1] (see Fig-
ure 1). Recent research in the field of joint models (Yu et al. 2008; Proust-Lima and Taylor
2009; Rizopoulos 2011, 2012; Taylor et al. 2013) has shown how such conditional survival
probabilities can be computed in order to identify for which subjects we need to proceed
in planning the next measurement. In particular, the fact that biomarker measurements
have been recorded up to t, implies that subject j was event-free up to this time point, and
therefore we are interested in:
pij(u | t) = Pr
{
T ∗j > u | T ∗j > t,Yj(t),Dn
}
, (8)
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where Yj(t) = {yj(tjl); 0 ≤ tjl ≤ t, l = 1, . . . , nj} denotes the longitudinal measurements of
subject j taken before t, and Dn = {Ti, δi,yi; i = 1, . . . , n} denotes the original dataset.
As we have seen in Section 2, in general, defining a joint model entails choosing an
appropriate model for the longitudinal outcome (i.e., baseline covariates and functional form
of the time effect), an appropriate model for the time-to-event (i.e., baseline covariates), and
how to link the two outcomes using function f(·). Hence, a relevant question is which model
to use for deciding when to plan the next measurement of subject j. Standard approaches for
model selection within the Bayesian framework include the deviance information criterion
(DIC) and (pseudo-) Bayes factors. However, a potential problem with these methods is that
they provide an overall assessment of a model’s predictive ability, whereas we are interested
in the model that best predicts future events given the fact that subject j was event-free up to
time point t. To identify the model to use at t we follow similar arguments as in Commenges
et al. (2012), and focus on the conditional density function of the survival outcome given the
longitudinal responses and survival up to t. More specifically, we let M = {M1, . . . ,MK}
denote a set of K joint models fitted to the original dataset Dn. Due to the fact that the
choice of the optimal model in M is based on a finite sample, an important issue we need
to address is overfitting. Hence, to obtain an objective estimate of the predictive ability of
each model we will use the cross-validatory posterior predictive conditional density of the
survival outcome, which for model Mk is defined as p
{
T ∗i | T ∗i > t,Yi(t),Dn\i,Mk
}
, where
Dn\i = {Ti′ , δi′ ,yi′ ; i′ = 1, . . . , i − 1, i + 1, . . . , n} denotes the version of the dataset that
excludes the responses of the i-th subject. Similarly we can define the same distribution
under model M∗, which denotes the model under which the data have been generated (M∗
is not required to be inM). Using conventional quantities of information theory (Cover and
Thomas 1991), we select the model Mk in the set M that minimizes the cross-entropy:
CEk(t) = E
{
− log
[
p
{
T ∗i | T ∗i > t,Yi(t),Dn\i,Mk
}]}
,
where the expectation is taken with respect to p(T ∗i | T ∗i > t,Yi(t),Dn\i,M∗). An estimate
of CEk(t) that accounts for censoring can be obtained using the available information in the
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sample at hand. We term this estimate the cross-validated Dynamic Conditional Likelihood :
cvDCLk(t) =
1
nt
n∑
i=1
−I(Ti > t) log p
{
Ti, δi | Ti > t,Yi(t),Dn\i,Mk
}
, (9)
where nt =
∑
i I(Ti > t). In turn, an estimate of p
{
Ti, δi | T ∗i > t,Yi(t),Dn\i,Mk
}
can be
obtained from the MCMC sample of model Mk by utilizing a similar computation as for the
conditional predictive ordinate statistic (Chen et al. 2008, condition on Mk is dropped in
the following expressions but is assumed):
[
p
{
Ti, δi | Ti > t,Yi(t),Dn\i
}]−1
=
p{Dn\i, Ti > t,Yi(t)}
p{Ti, δi, Ti > t,Yi(t),Dn\i}
=
∫
p(Dn\i | θ) p{Ti > t,Yi(t) | θ} p(θ)
p(Dn) dθ =
∫
p{Ti > t,Yi(t) | θ}
p{Ti, δi,Yi(t) | θ}
p(Dn | θ) p(θ)
p(Dn) dθ
=
∫
1
p{Ti, δi | Ti > t,Yi(t),θ} p(θ | Dn) dθ, (10)
where θ includes here both the parameters of the joint model θ, as defined in Section 2, and
the random effects. Hence, based on the MCMC sample from [θ | Dn] and identity (10) we
can obtain a Monte Carlo estimate of (9) as
cvDĈL(t) =
1
nt
n∑
i=1
I(Ti > t) log
(
1
G
G∑
g=1
1
p
{
Ti, δi | Ti > t,Yi(t),θ(g)
}), (11)
where θ(g) denotes here the g-th realization from the MCMC sample {θ(g); g = 1, . . . , G}.
Calculation of p
{
Ti, δi | Ti > t,Yi(t),θ(g)
}
is based on the conditional independence assump-
tions (4) and (5). Due to space limitations and the fact that similar calculations will be
required in the following section we do not show them in detail here.
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4 Scheduling Patterns based on Information Theory
4.1 Planning of the Next Measurement
Having chosen the appropriate model to use at time t, our aim next is to decide when to
plan the following measurement of subject j. Similarly to the previous section, the quantity
that we will use for making this decision is the posterior predictive conditional distribution
p{T ∗j | T ∗j > t,Yj(t),Dn}. This distribution again has a cross-validatory flavor because
j 6∈ {i = 1, . . . , n}. We let yj(u) denote the measurement of the longitudinal outcome at
the future time point u > t. For the selection of the optimal u we would like to maximize
the information we gain by measuring yj(u) at this time point, provided that the patient
was still event-free up to u. If the event occurs before time u for subject j, then there
is no gain in information. Using concepts from Bayesian optimal designs (Verdinelli and
Kadane 1992; Clyde and Chaloner 1996), this can be formally expressed using the utility
function (conditioning on baseline covariates wj is assumed in the following expressions but
is dropped for notational simplicity):
U(u | t) = E
{
λ1 log
p
(
T ∗j | T ∗j > u,
{Yj(t), yj(u)},Dn)
p{T ∗j | T ∗j > u,Yj(t),Dn}
+ λ2I(T
∗
j > u)
}
, (12)
where the expectation is taken with respect to the joint predictive distribution [T ∗j , yj(u) |
T ∗j > t,Yj(t),Dn]. Making the connection to the information theory concepts we used
in Section 3, the first term in (12) is the expected Kullback-Leibler divergence between
the posterior predictive conditional distributions with and without this extra measurement,
namely
EKL(u | t) = EY
[
ET ∗|Y
{
log
p
(
T ∗j | T ∗j > u,
{Yj(t), yj(u)},Dn)
p{T ∗j | T ∗j > u,Yj(t),Dn}
}]
(13)
=
∫ {∫
log
p
(
T ∗j | T ∗j > u,
{Yj(t), yj(u)},Dn)
p{T ∗j | T ∗j > u,Yj(t),Dn}
p
(
T ∗j | T ∗j > t,
{Yj(t), yj(u)},Dn) dT ∗j }
× p{yj(u) | T ∗j > t,Yj(t),Dn} dyj(u).
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Heuristically, for u close to t, in general, we would expect minimal information gain. Anal-
ogously, as u moves further away from t we would expect to gain information, but the value
of u that maximizes this information gain will depend on the characteristics of the subject’s
projected longitudinal profile. However, the ‘cost’ of waiting up to time u, is the fact that
we also inevitably increase the risk that the patient will experience the event. Because we
would not like to wait up to a point that it would be late for the physician to intervene (e.g.,
the event already happened), we need to counterbalance these two aspects, which motivates
including the second term in (12). The expectation with respect to this second term is the
conditional survival probability pij(u | t) introduced in (8). Hence, (12) becomes
U(u | t) = λ1EKL(u | t) + λ2pij(u | t).
The purpose of the nonnegative constants λ1 and λ2 is to weigh the contribution of the
cumulative risk as opposed to the information gain, and to take into account that these two
terms have different units. In practical applications, elicitation of these constants for trading
information units with probabilities can be difficult. However, using the equivalence between
compound and constrained optimal designs (Cook and Wong 1994; Clyde and Chaloner
1996), it can be shown that for any λ1 and λ2, there exists a constant κ ∈ [0, 1] for which
maximization of (12) is equivalent to maximization of EKL(u | t) subject to the constraint
that pij(u | t) ≥ κ. Under this equivalent formulation elicitation of κ is relatively easier;
for example, a logical choice is to set κ equal to the constant c(t), introduced in Figure 1,
for deciding whether the physician is supposed to intervene or not. In turn, a choice of
c(t) can be based on medical grounds or on time-dependent receiver operating characteristic
(ROC) analysis. Then, the optimal value of u can be found by maximizing EKL(u | t) in
the interval (t, tup], where tup = {u : pij(u | t) = κ}. In practice, it also may be reasonable
to assume that there is an upper limit tmax of the time interval the physician is willing to
wait to obtain the next measurement, in which case tup = min{u : pij(u | t) = κ, tmax}. The
advantageous feature of this approach is that the optimal u is found by conditioning on both
the baseline characteristics wj and accumulated longitudinal information Yj(t) of subject j.
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This allows one to better tailor screening to the subject’s individual characteristics compared
to approaches that only utilize the baseline covariates and the last available longitudinal
measurement (Markov assumption).
4.2 Estimation
Estimation of (12) proceeds by suitably utilizing the conditional independence assump-
tions (4) and (5). More specifically, the density of the joint distribution [T ∗j , yj(u) | T ∗j >
t,Yj(t),Dn] can be written as the product of the predictive distributions,
p
(
T ∗j | T ∗j > t,
{Yj(t), yj(u)},Dn) = ∫ p(T ∗j | T ∗j > t,{Yj(t), yj(u)},θ) p(θ | Dn) dθ,
and,
p{yj(u) | T ∗j > t,Yj(t),Dn} =
∫
p{yj(u) | T ∗j > t,Yj(t),θ} p(θ | Dn) dθ.
Analogously, the first term in the right-hand side of each (4.2) and (4.2) can be written as
expectations over the corresponding posterior distributions of the random effects of subject
j, i.e.,
p{yj(u) | T ∗j > t,Yj(t),θ} =
∫
p{yj(u) | bj,θ} p{bj | T ∗j > t,Yj(t),θ} dbj,
and,
p
(
T ∗j | T ∗j > t,
{Yj(t), yj(u)},θ)
=
∫
p(T ∗j | T ∗j > t, bj,θ) p{bj | T ∗j > t,
{Yj(t), yj(u)},θ} dbj,
13
respectively. In a similar manner, the density of the predictive distribution [T ∗j | T ∗j >
u,
{Yj(t), yj(u)},Dn] is written as:
p(T ∗j | T ∗j > u,
{Yj(t), yj(u)},Dn)
=
∫ ∫
p(T ∗j | T ∗j > u, bj,θ) p(bj | T ∗j > u,
{Yj(t), yj(u)},θ) p(θ | Dn) dbjdθ,
with
p(T ∗j | T ∗j > u, bj,θ) =
hj
(
T ∗j | Hj
(
t, bj,θ
))
exp
{
−
∫ T ∗j
0
hj
(
s | Hj
(
t, bj,θ
))
ds
}
exp
{
−
∫ u
0
hj
(
s | Hj
(
t, bj,θ
))
ds
} ,
and the hazard function is given by (2), in which we have explicitly noted that the history
of the longitudinal process Hj
(
t, bj,θ
)
is a function of both the random effects and the
parameters, because it is estimated from the mixed model (1). By combining the above
equations we can construct a Monte Carlo simulation scheme to obtain an estimate of (12)
for a specific value of u. This scheme contains the following steps that should be repeated
q = 1, . . . , Q times:
Step 1: Simulate θ˜, θ¨, and {θ˘(`), ` = 1, . . . , L} independently from the posterior distribution
of the parameters [θ | Dn].
Step 2: Simulate b˜j from the posterior of the random effects [bj | T ∗j > t,Yj(t), θ˜].
Step 3: Simulate y˜j(u) from [yj(u) | b˜j, θ˜].
Step 4: Simulate b¨j and {b˘(`)j , ` = 1, . . . , L} independently from the posterior of the random
effects [bj | T ∗j > t, {Yj(t), y˜j(u)}, θ¨] and [bj | T ∗j > u, {Yj(t), y˜j(u)}, θ˘
(`)
], respectively.
Step 5: Simulate T¨ ∗j from [T
∗
j | T ∗j > u, b¨j, θ¨].
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Step 6: If T¨ ∗j > u, compute EKL
(q)(u | t) = log
{
L−1
L∑
`=1
A(`)n
/A(`)d }, where
A(`)n = hj
(
T¨ ∗j | Hj
(
T¨ ∗j , b˘
(`)
j , θ˘
(`)))
exp
{
−
∫ T¨ ∗j
0
hj
(
s | Hj
(
s, b˘
(`)
j , θ˘
(`)))
ds
}
,
and
A(`)d = exp
{
−
∫ u
0
hj
(
s | Hj
(
s, b˘
(`)
j , θ˘
(`)))
ds
}
;
otherwise set EKL(q)(u | t) = 0.
The sample mean over the Monte Carlo samples provides the estimate of EKL(u | t), i.e.,
EK̂L(u | t) = Q−1∑Qq=1 EKL(q)(u | t). The posterior distribution of the random effects in
Steps 2 and 4 is not of a known form, and therefore the realizations b˜j, b¨j and {b˘(`)j , ` =
1, . . . , L} are obtained using a Metropolis-Hastings algorithm, with proposal distribution a
multivariate Student’s-t distribution with mean b̂ = arg maxb{log p(b | T ∗j > t,Yj(t), θ̂)},
variance-covariance matrix V =
{−∂2 log p(b | T ∗j > t,Yj(t), θ̂)/∂b>∂b∣∣b=bˆ}−1, and four
degrees of freedom, where θ̂ denotes the posterior means based on [θ | Dn]. Step 3 just
entails simulating a realization from the mixed effects model. In Step 5 again the distribution
[T ∗j | T ∗j > t, b¨j, θ¨] is not of standard form, and hence we simulate the realization T¨ ∗j using
the inversion method, i.e., first we simulate v ∼ U(0, 1), and then using a line-search method
we find the T¨ ∗j for which Sj(T¨
∗
j , b¨j, θ¨)
/
Sj(t, b¨j, θ¨) = v, with Sj(·) given by (7). Finally, in
Step 6 it is sufficient to compute the numerator of (13) to obtain the optimal u. An estimate
of pij(u | t) can be obtained from a separate Monte Carlo scheme (see e.g., Rizopoulos 2011)
pij(u | t) = 1
G
G∑
g=1
exp
{
−
∫ u
0
hj
(
s | Hj
(
s, b˚
(g)
j , θ˚
(g)))
ds
}
exp
{
−
∫ t
0
hj
(
s | Hj
(
s, b˚
(g)
j , θ˚
(g)))
ds
} ,
with {θ˚(g), g = 1, . . . , G} a sample from [θ | Dn], and b˚(g)j a sample from [bj | T ∗j >
t,Yj(t), θ˚(g)]. Based on the Monte Carlo sample of EKL(u | t) a 95% credible interval
van be constructed using the corresponding Monte Carlo sample percentiles. Using this sim-
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ulation scheme we take as optimal u the value uˆ = arg maxu∈{u1,...,umax}{EKL(u | t)}, subject
to the constraint that pij(u | t) ≥ κ, with u1, . . . , umax denoting a grid of values in (t, tup].
5 Analysis of the Aortic Valve Dataset
We return to the Aortic Valve dataset introduced in Section 1. Our aim is to use the existing
data to build joint models that can be utilized for planning the visiting patterns of future
patients from the same population. In our study, a total of 77 (27%) patients received a
sub-coronary implantation (SI) and the remaining 208 patients a root replacement (RR).
These patients were followed prospectively over time with annual telephone interviews and
biennial standardized echocardiographic assessment of valve function until July 8, 2010.
Echo examinations were scheduled at 6 months and 1 year postoperatively, and biennially
thereafter, and at each examination, echocardiographic measurements were taken. By the
end of follow-up, 1262 assessments have been recorded, with an average of 4.3 measurements
per patient (s.d. 2.4 measurements), 59 (20.7%) patients had died, and 73 (25.6%) patients
required a re-operation on the allograft. Here we are interested in the composite event
re-operation or death, which was observed for 125 (43.9%) patients.
We start by defining two sets of joint models that we will use for planning measurements
of future patients. Each set considers a separate longitudinal outcome that measures the
functioning of the aortic valve, namely, the square root transform of aortic gradient (con-
tinuous outcome) and the aortic regurgitation (binary outcome). Preliminary analysis using
plots of the subject-specific trajectories of the two outcomes, and fitting linear mixed effects
and mixed effects logistic regression models suggested nonlinear profiles for aortic gradient
and linear evolutions for the logit (logit(x) = log{x/(1 − x)}) of the probabilities of aortic
regurgitation. Hence, we let yi,1 denote the continuous aortic gradient longitudinal outcome,
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and yi,2 the binary aortic regurgitation outcome and postulate the models
yi,1(t) = (β0,1 + bi0,1) + (β1,1 + bi1,1)Bn(t, 1) + (β2,1 + bi2,1)Bn(t, 2)
+ β3,1Agei + β4,1Femalei + εi(t),
where Bn(t, {1, 2}) denotes the B-spline basis for a natural cubic spline with boundary knots
at baseline and 19 years and one internal knot placed at 3.7 years (i.e., the median of the
observed follow-up times), Female denotes the dummy variable for females, and
logit
[
Pr{yi,2(t) = 1}
]
= (β0,2 + bi0,2) + (β1,2 + bi1,2)t+ β2,2Agei + β3,2Femalei.
Both bi,1 and bi,2 are assumed to follow multivariate normal distributions with mean zero
and covariance matrices D1 and D2, respectively. For the survival process we consider four
relative risk models, each positing a different association structure between the two processes,
namely:
M1,k : hi,k(t) = h0,k(t) exp
{
γ1,kAgei + γ2,kFemalei + α1,kηi,k(t)
}
,
M2,k : hi,k(t) = h0,k(t) exp
{
γ1,kAgei + γ2,kFemalei + α2,kη
′
i,k(t)
}
,
M3,k : hi,k(t) = h0,k(t) exp
{
γ1,kAgei + γ2,kFemalei + α1,kηi,k(t) + α2,kη
′
i,k(t)
}
,
M4,k : hi,k(t) = h0,k(t) exp
{
γ1,kAgei + γ2,kFemalei + α1,k
∫ t
0
ηi,k(s)ds
}
,
M5,k : hi,k(t) = h0,k(t) exp
(
γ1,kAgei + γ2,kFemalei +α
>
k bi,k
)
,
where k = 1, 2 denotes the relative risk models corresponding to the two sets of joint models
for aortic gradient and aortic regurgitation, respectively. The baseline hazard was approxi-
mated using penalized B-splines approach described in Section 2. For all parameters we took
standard prior distributions (Ibrahim et al. 2001; Brown and Ibrahim 2003; Brown 2009).
In particular, for the vector of fixed effects of the longitudinal submodel β, the regression
parameters of the survival model γ, the vector of spline coefficients for the baseline hazard
γh0 , and for the association parameter α we used independent univariate diffuse normal
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priors. For the variance of the error terms σ2 we take an inverse-Gamma prior, while for
covariance matrices we assumed an inverse Wishart prior.
Tables 1 and 2 present the posterior means and 95% credible intervals of the parameters of
the joint models for aortic gradient and aortic regurgitation fitted to the Aortic Valve data.
With respect to the parameters of the longitudinal component we do not observe great
M1,1 M2,1 M3,1 M4,1 M5,1
Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI)
Intercept 3.67 (3.33; 4.00) 3.66 (3.32; 4.01) 3.68 (3.34; 4.03) 3.67 (3.34; 4.02) 3.67 (3.32; 4.02)
B-spln1 3.28 (2.79; 3.83) 3.37 (2.84; 3.89) 3.31 (2.81; 3.84) 3.26 (2.76; 3.75) 3.34 (2.85; 3.83)
B-spln2 2.70 (2.33; 3.13) 2.77 (2.34; 3.21) 2.72 (2.35; 3.13) 2.68 (2.28; 3.08) 2.72 (2.31; 3.15)
Age -0.02 (-0.02; -0.01) -0.02 (-0.02; -0.01) -0.02 (-0.02; -0.01) -0.02 (-0.02; -0.01) -0.02 (-0.02; -0.01)
Female 0.17 (-0.06; 0.40) 0.17 (-0.06; 0.39) 0.17 (-0.04; 0.41) 0.18 (-0.05; 0.41) 0.18 (-0.04; 0.41)
σ 0.61 (0.58; 0.65) 0.62 (0.58; 0.65) 0.62 (0.58; 0.65) 0.61 (0.58; 0.65) 0.62 (0.58; 0.66)
d11 0.64 (0.48; 0.83) 0.62 (0.47; 0.80) 0.63 (0.48; 0.84) 0.64 (0.47; 0.82) 0.61 (0.46; 0.81)
d21 -0.69 (-1.44; -0.06) -0.51 (-1.19; 0.10) -0.64 (-1.38; -0.04) -0.69 (-1.42; -0.05) -0.53 (-1.23; 0.12)
d31 -0.43 (-1.05; 0.09) -0.40 (-0.97; 0.15) -0.43 (-1.00; 0.13) -0.46 (-1.10; 0.11) -0.34 (-0.96; 0.28)
d22 13.61 (9.66; 18.74) 13.87 (9.79; 19.14) 13.50 (9.76; 18.14) 13.91 (9.85; 19.09) 13.06 (9.26; 17.83)
d32 8.14 (4.40; 13.62) 9.46 (5.84; 14.20) 8.05 (4.55; 12.82) 8.70 (4.61; 13.66) 8.01 (4.09; 13.47)
d33 7.04 (3.11; 12.99) 8.08 (4.62; 13.25) 6.63 (3.32; 11.71) 7.80 (3.55; 14.06) 7.31 (3.06; 15.57)
M1,2 M2,2 M3,2 M4,2 M5,2
Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI)
Intercept -2.01 (-3.74; -0.34) -2.03 (-3.80; -0.41) -1.89 (-3.43; -0.32) -2.03 (-3.64; -0.43) -1.98 (-3.57; -0.32)
time 0.38 (0.28; 0.48) 0.39 (0.29; 0.49) 0.39 (0.29; 0.50) 0.37 (0.27; 0.47) 0.40 (0.29; 0.49)
Age -0.03 (-0.07; -0.00) -0.03 (-0.07; 0.00) -0.03 (-0.07; -0.00) -0.03 (-0.07; -0.00) -0.03 (-0.07; -0.00)
Female 1.40 (0.29; 2.55) 1.40 (0.28; 2.56) 1.26 (0.23; 2.24) 1.43 (0.31; 2.51) 1.35 (0.25; 2.44)
d11 14.29 (8.77; 22.97) 14.04 (9.16; 21.57) 11.01 (7.19; 16.10) 13.39 (8.18; 20.15) 12.64 (8.08; 18.83)
d21 -0.56 (-1.47; 0.17) -0.38 (-1.11; 0.24) 0.06 (-0.58; 0.63) -0.48 (-1.31; 0.22) -0.18 (-0.92; 0.46)
d22 0.47 (0.27; 0.80) 0.44 (0.24; 0.73) 0.48 (0.27; 0.84) 0.52 (0.30; 0.90) 0.43 (0.25; 0.74)
Table 1: Estimated coefficients and 95% credibility intervals for the parameters of the lon-
gitudinal submodels fitted to the Aortic Valve dataset. The top part of the table refers to
the results for aortic gradient and the bottom part for aortic regurgitation. dij denotes the
ij-th element of the corresponding covariance matrix of the random effects.
M1,1 M2,1 M3,1 M4,1 M5,1
Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI)
Age 0.02 (0.01; 0.04) 0.02 (0.01; 0.04) 0.02 (0.01; 0.04) 0.02 (0.00; 0.03) 0.02 (0.01; 0.04)
Female -0.09 (-0.48; 0.29) -0.02 (-0.43; 0.36) -0.09 (-0.49; 0.30) -0.10 (-0.51; 0.29) 0.01 (-0.43; 0.45)
α1 0.19 (0.09; 0.30) 0.16 (0.02; 0.30) 0.02 (0.01; 0.03) -0.03 (-0.59; 0.51)
α2 2.40 (1.07; 3.82) 0.78 (-1.76; 2.99) 0.43 (0.26; 0.65)
α3 -0.02 (-0.75; 0.81)
M1,2 M2,2 M3,2 M4,2 M5,2
Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI)
Age 0.01 (-0.00; 0.03) 0.01 (-0.00; 0.03) 0.01 (-0.00; 0.03) 0.01 (-0.00; 0.02) 0.02 (0.00; 0.03)
Female -0.02 (-0.43; 0.36) -0.01 (-0.44; 0.40) 0.07 (-0.40; 0.52) 0.00 (-0.40; 0.41) -0.02 (-0.51; 0.43)
α1 0.03 (-0.00; 0.07) -0.09 (-0.18; -0.01) 0.001 (-0.002; 0.004) -0.06 (-0.22; 0.04)
α2 1.13 (0.32; 2.32) 2.31 (0.84; 4.17) 1.46 (0.43; 3.63)
Table 2: Estimated coefficients and 95% credibility intervals for the parameters of the sur-
vival submodels fitted to the Aortic Valve dataset. The top part of the table refers to the
results for aortic gradient and the bottom part for aortic regurgitation.
differences between the fitted joint models for both aortic gradient and aortic regurgitation.
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For the relative risk submodels and for aortic gradient we see that when the terms ηi,1(t)
and η′i,1(t) are independently included in the model both of them show to be related with the
risk of re-operation/death, however, when both of them are included in the model, the slope
term η′i,1(t) does not seem to be associated with the hazard of the event anymore. Moreover,
the area under the subject-specific longitudinal profile up to time t is also strongly related
to the risk for event at same time point, indicating that not only features of the trajectory
at time t are important but also at previous time points. For aortic regurgitation we observe
that when combined, both the current value and the current slope term are associated with
the risk of the composite event, whereas past values (i.e., the cumulative effect) do not seem
to contribute in predicting future events.
We continue by investigating the performance of the fitted joint models with respect to
predicting future events after different follow-up times. Table 3 shows the DIC and the value
of cvDĈL(t) × nt for t = 5, 7, 9, 11 and 13. From the set of joint models fitted with aortic
M1,1 M2,1 M3,1 M4,1 M5,1
DIC 7237.26 7186.18 7195.57 7268.45 7186.34
cvDĈL(t = 5)× nt -387.67 -348.96 -380.82 -441.69 -356.31
cvDĈL(t = 7)× nt -342.75 -309.69 -336.95 -391.78 -315.26
cvDĈL(t = 9)× nt -289.11 -260.44 -284.13 -332.06 -264.95
cvDĈL(t = 11)× nt -233.56 -208.11 -229.27 -270.28 -212.06
cvDĈL(t = 13)× nt -177.10 -156.88 -173.58 -206.40 -160.03
M1,2 M2,2 M3,2 M4,2 M5,2
DIC 4166.76 4114.27 4049.99 4186.72 4061.53
cvDĈL(t = 5)× nt -370.46 -362.97 -328.10 -358.95 -365.31
cvDĈL(t = 7)× nt -328.84 -321.25 -288.47 -318.74 -322.70
cvDĈL(t = 9)× nt -278.23 -272.55 -244.73 -269.81 -273.23
cvDĈL(t = 11)× nt -223.45 -218.67 -195.18 -216.21 -219.19
cvDĈL(t = 13)× nt -170.24 -167.14 -147.95 -164.21 -167.95
Table 3: DIC and cvDĈL(t) evaluated at five time points for the fitted joint models.
gradient as the biomarker we observe that models M2,1 and M5,1 have almost identical DIC
values but according to cvDĈL(t) model M2,1 provides the best predictions for future events.
For aortic regurgitation model M3,2 is selected as the best model according to both DIC and
cvDĈL(t). However, as a side note we observe that model M5,2 has a lower DIC value than
M4,2 but the cvDĈL(t) was higher for model M4,2 for all t, which again suggests that the
DIC, as a global measure, may not always select the model that more accurately predicts
future events after a particular time point t.
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To illustrate the use of the methodology developed in Section 4 for selecting the next
screening time point, we focus on the continuous marker and two patients from the Aortic
Valve dataset, namely Patient 81 who is a male of 39.8 years old, and Patient 7 who is a
male of 46.8 years old and neither had an event. These patients have been explicitly selected
because of the shape of their longitudinal trajectories of the square root aortic gradient,
shown in Figure 2. More specifically, Patient 7 exhibits a slightly increasing trajectory of
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Figure 2: Longitudinal trajectories of the square root aortic gradient for Patients 7 and 81.
aortic gradient indicating that he remained in relatively good condition during the follow-up,
whereas Patient 81 showed an increasing profile of aortic gradient indicative of a deterioration
of his condition. We should note that in accordance with a realistic use of (12) for planning
the next measurement, the joint models presented above have been fitted in the version of
the Aortic Valve dataset that excluded those two patients. Tables 4 and 5 show the values
of EKL(u | t) (i.e., the first term of (12)), and of pij(u | t) (i.e., the second term of (12)) for
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these two patients computed in a dynamic manner, namely, after each of their longitudinal
measurements (i.e., time point t). The upper limit tup of the interval (t, tup] was set as the
minimum of tmax = 5 years and the time point u for which pij(u | t) was equal to κ = 0.8.
Then the optimal u was taken as the point that maximizes EKL(u | t) in a grid of five
equidistant values in the interval (t, tup]. All calculations have been based on joint model
M2,1. For Patient 7, who remained relatively stable during the first period of his follow-up,
t tup − t u EKL(u | t) pij(u | t)
0.3 5 1.3 -2.488 0.989
2.3 -2.205 0.977
3.3 -2.227 0.963
4.3 -2.197 0.948
5.3 -2.153 0.933 *
1.3 5 2.3 -2.176 0.987
3.3 -2.127 0.973
4.3 -1.963 0.957
5.3 -2.088 0.940
6.3 -1.868 0.922 *
3.3 5 4.3 -2.143 0.978
5.3 -1.436 0.956 *
6.3 -2.015 0.932
7.3 -1.913 0.905
8.3 -1.634 0.875
5.3 3.9 6.1 -2.143 0.968
6.9 -1.603 0.935 *
7.6 -1.879 0.900
8.4 -1.967 0.864
9.2 -1.750 0.827
7.1 2.1 7.5 -1.888 0.969 *
7.9 -1.993 0.937
8.4 -1.963 0.906
8.8 -1.901 0.875
9.2 -2.104 0.844
10.6 1.7 11.0 -0.243 0.970
11.3 -0.156 0.940 *
11.6 -1.397 0.910
12.0 -0.542 0.880
12.3 -2.184 0.849
Table 4: The values of EKL(u | t) (i.e., the first term of (12)), pij(u | t) (i.e., the second
term of (12)), for Patient 81 computed in a dynamic manner, after each of his longitudinal
measurements (i.e., time point t), and for u set as a regular sequence from t to t+3 of length
five. The last column denotes which time point is selected to plan the next measurement.
we observe that EKL(u | t) always suggests waiting the full five years up to measurement
seven; however, after the seventh measurement and because his profile started to slightly
increase and his relative older age, the length of the interval (t, tup] for finding the optimal
u decreases, which in turn suggests to wait after each visit less time before requesting the
next echocardiography. For Patient 81 on the other hand we observe that for the first two
visits, where he exhibited relatively low levels of aortic gradient, EKL(u | t) suggests to wait
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for a longer period years before requesting the next measurement. In accordance, tup is set
to five years because the probability that he will survive more than five years was higher
than κ = 0.8. After the third measurement however, when it starts to become clear that the
condition of this patient deteriorates, EKL(u | t) recommends to wait less time to request
the next echocardiography. Accordingly from the fourth measurement onwards the length
of the interval (t, tup] decreases and in the last measurement is set to 1.7 years that also
indicates the deterioration of the patient.
6 Discussion
In this paper we have presented two measures based on information theory that can be used
to dynamically select models in time and optimally schedule longitudinal biomarker mea-
surements. Contrary to standard screening procedures that require all patients to adhere to
the same screening intervals, the combination of the framework of joint models for longitu-
dinal and time-to-event data with these two measures allows one to tailor screening to the
needs of individual patients and dynamically adapt during follow-up.
Motivated by the aim of the Aortic Valve dataset, in this work we have concentrated
on a single endpoint. Nevertheless, using recent advances in the joint modeling literature
(Andrinopoulou et al. 2014; Dantan et al. 2011) the same ideas can be relatively easily
extended to multiple endpoints (competing risks) or intermediate states combined with one
or several endpoints (multistate settings). In such settings the first term of (12) will remain
the same, but the second term pij(u | t) will need to be replaced by the corresponding
cumulative incidence function. Furthermore, our approach also could be combined with
concepts, such as the value of information (Koerkamp et al. 2006) to incorporate the relative
costs of measuring the biomarker.
Finally, to facilitate the computation of cvDĈL(t) and EK̂L has been implemented in
functions cvDCL() and dynInfo(), respectively, available in package the JMbayes (ver-
sion 0.7-0; Rizopoulos 2015) for the R programming language (freely available from the
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Comprehensive R Archive Network at http://cran.r-project.org/package=JMbayes).
A working example of how these functions should be used can be found in the supplemen-
tary material.
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t tup − t u EKL(u | t) pij(u | t)
3.5 5 4.5 -2.363 0.983
5.5 -2.354 0.964
6.5 -2.306 0.943
7.5 -2.279 0.919
8.5 -2.065 0.892 *
4 5 5.0 -2.366 0.982
6.0 -2.422 0.963
7.0 -2.210 0.941
8.0 -2.214 0.915
9.0 -2.106 0.886 *
5 5 6.0 -2.416 0.981
7.0 -2.470 0.959
8.0 -2.261 0.933
9.0 -2.300 0.904
10.0 -2.146 0.872 *
5.7 5 6.7 -2.455 0.979
7.7 -2.410 0.956
8.7 -2.311 0.928
9.7 -2.352 0.897
10.7 -2.207 0.861 *
6.7 5 7.7 -2.426 0.976
8.7 -2.389 0.949
9.7 -2.328 0.917
10.7 -2.304 0.882
11.7 -2.235 0.841 *
7.7 5 8.7 -2.403 0.973
9.7 -2.394 0.941
10.7 -2.307 0.906
11.7 -2.272 0.865
12.7 -2.171 0.819 *
9.1 4.3 9.9 -2.355 0.971
10.8 -2.335 0.939
11.7 -2.201 0.903
12.5 -2.130 0.863
13.4 -2.096 0.817 *
11.3 3.1 11.9 -2.202 0.969
12.5 -2.044 0.935
13.1 -2.003 0.897
13.8 -1.908 0.856 *
14.4 -1.920 0.810
13.5 1.9 13.9 -1.919 0.968
14.3 -1.855 0.933
14.7 -1.742 0.897
15.1 -1.655 0.858 *
15.4 -1.719 0.817
15.1 1.4 15.4 -1.769 0.968
15.7 -1.731 0.934
15.9 -1.632 0.899
16.2 -1.560 0.862
16.5 -1.536 0.824 *
Table 5: The values of EKL(u | t) (i.e., the first term of (12)), pij(u | t) (i.e., the second
term of (12)), for Patient 7 computed in a dynamic manner, after each of his longitudinal
measurements (i.e., time point t), and for u set as a regular sequence from t to t+3 of length
five. The last column denotes which time point is selected to plan the next measurement.
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